Reitz Capital Advisors’s Moderna MRNA Stock Holding History

Reitz Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-175	Closed	-$30K	–	67
2022 Q1	$30K	Buy	+175	New	+$29.5K	0.02%	67

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Reitz Capital Advisors's MRNA Position: Q2 2022 in Review

Reitz Capital Advisors sold out of Moderna (MRNA) in Q2 2022, closing a stake of 175 shares — an estimated $30K sold.

Reitz Capital Advisors first reported a position in MRNA in Q1 2022 and held it in 1 quarter. The position peaked at $30K in Q1 2022. 980 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

Reitz Capital Advisors reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
Reitz Capital Advisors sold 175 Moderna shares in Q2 2022, an estimated $30K.
Reitz Capital Advisors first reported a position in Moderna in Q1 2022 and held it in 1 quarter.
Reitz Capital Advisors's Moderna position peaked at $30K in Q1 2022.
980 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on Reitz Capital Advisors's 13F filing for Q2 2022, filed 20 Jul 2022.